Market Place
Sourcing Support
Kazia prunes failed cancer trial data set to form path to FDA
11 Jul 2024 //
PR NEWSWIRE
Kazia Announces The Release Of Pnoc022 Clinical Study Abstract
15 Nov 2023 //
PR NEWSWIRE
Kazia Announces Publication In Cancer Therapeutics Highlighting Paxalisib Data
10 Nov 2023 //
PR NEWSWIRE
Kazia Provides Preliminary Update From Ongoing Phase 2 Study Of Paxalisib
01 Nov 2023 //
PR NEWSWIRE
PNOC Clinical Study Of Kazia`s Paxalisib In Childhood Brain Cancer Expands
06 Oct 2022 //
BENZINGA
Kazia Tx Reports Promising Interim Data From Combination Study Of Paxalisib
05 Aug 2022 //
PRNEWSWIRE
Kazia dropped from global umbrella trial to treat brain cancer
01 Aug 2022 //
FIERCEBIOTECH
FDA Awards RPDD To Paxalisib For At/Rt
06 Jul 2022 //
PRNEWSWIRE
FDA Awards ODD To Paxalisib For At/Rt, A Rare Form Of Childhood Brain Cancer
17 Jun 2022 //
PRNEWSWIRE
Kazia reports positive results from Phase II trial of glioblastoma therapy
06 Dec 2021 //
CLINICALTRIALSARENA
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib
04 Dec 2021 //
PRNEWSWIRE
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
30 Jun 2021 //
PR NEWSWIRE
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma
24 Aug 2020 //
PRNEWSWIRE
US FDA grants orphan drug status to Kazia Therapeutics; paxalisib
24 Aug 2020 //
PHARMABIZ
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma
24 Aug 2020 //
PRNEWSWIRE
FDA Grants Fast Track Designation to Paxalisib in Glioblastoma
20 Aug 2020 //
PRESS RELEASE
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing +VE
22 Jun 2020 //
PRNEWSWIRE
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Survival
01 Jun 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.